Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 200 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Sean O.

United States

USD 200 /hr

Biotech strategist | Expert in IND, translational R&D & scientific writing for pitch decks, grants & BD

Profile Summary

I am a biotech executive and Ph.D. scientist with over 20 years of experience in oncology drug development, translational R&D, and strategic leadership across early-stage startups and publicly traded biopharma. I’ve founded and led multiple biotech companies, advanced small molecule oncology and antiviral programs from discovery to Phase II, and negotiated multimillion-dollar licensing and funding deals. My expertise spans IND strategy, preclinical development, PK/PD, CMC planning, IP positioning, and cross-functional team leadership. I have a strong publication and patent record and have designed and overseen global clinical trials and CRO collaborations. I offer freelance support in: Translational & IND strategy Scientific writing (grants, investor decks, white papers) Due diligence and asset evaluations Competitive landscape and pipeline analysis

Subject Matter Expertise

• ☆ Chemoinformatics
• ☆ Computational Chemistry
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ DNA Sequencing
• ☆ Protein Sequencing
• ☆ Gene Expression Analysis
• ☆ DNA Damage & Repair
• ☆ Cell-Based Assays
• ☆ Cell Signaling Pathways
• ☆ Information Retrieval
• ☆ Drug Discovery
• ☆ High Throughput Screening (HTS)
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ Phenotypic Assays
• ☆ High Content Screening/Imaging
• ☆ Medicinal Chemistry
• ☆ Drug Design
• ☆ Structure-Activity Relationship (SAR) Studies
• ☆ Drug Development
• ☆ Small Molecule Drug Development
• ☆ Preclinical ADME/PK/PD
• ☆ Drug-Drug Interactions
• ☆ Preclinical Research
• ☆ Preclinical Pharmacology
• ☆ In vitro Preclinical Toxciology
• ☆ In vivo Preclinical Toxicology
• ☆ Investigational New Drug (IND) Application Consulting
• ☆ Drug Efficacy Testing
• ☆ Bioavailability
• ☆ Clinical Trials
• ☆ Oncology
• ☆ Chemotherapy
• ☆ Precision Medicine
• ☆ Pediatric Oncology
• ☆ Hematology
• ☆ Hematology-Oncology
• ☆ Leukemia & Lymphoma

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Medical Writing, Technical Writing, Business & Legal Writing

Research Market Research, User Research, Technology Scouting

Consulting Business Strategy Consulting

Data & AI Predictive Modeling, Algorithm Design-Non ML, Algorithm Design-ML

Work Experience

Founder and CEO

Sisu Pharma

2020 - Present

Founder and CEO

G4 Oncology

2017 - 2019

Co-Founder & VP, Corporate Affairs

Trilogy Therapeutics

2015 - 2017

VP, Corporate Development

Senhwa Biosciences

2013 - 2015

VP, Research & Business Development

Cylene Pharmaceuticals

2005 - 2013

Computational Chemist

Pfizer (United States)

2002 - 2004

Computational Chemist

Cancer Research Laboratories UK

January 2000 - January 2002

Education

Ph.D. (Chemistry)

University of Manchester Institute of Science and Technology

1997 - 2000

M.Chem w. French (Chemistry)

University of Manchester Institute of Science and Technology

1991 - 1996

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Dong, Qianze, Xiu, Yan, Wang, Yang, Hodgson, Christina, Borcherding, Nick, Jordan, Craig, Buchanan, Jane, Taylor, Eric, Wagner, Brett, Leidinger, Mariah, et al.(2022). HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia. Nature communications. 13. (1). p. 6107. Nature Publishing Group UK London

Yu, Iching G, O'Brien, Sean E, Ryckman, David M(2021). Pharmacokinetic and pharmacodynamic comparison of intravenous and inhaled caspofungin. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 34. (3). p. 197--203. Mary Ann Liebert, Inc., publishers 140 Huguenot Street, 3rd Floor New~…

Lee, Hans C, Wang, Hua, Baladandayuthapani, Veerabhadran, Lin, Heather, He, Jin, Jones, Richard J, Kuiatse, Isere, Gu, Dongmin, Wang, Zhiqiang, Ma, Wencai, et al.(2017). RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. British journal of haematology. 177. (1). p. 80--94.

Miyabe, Katsuyuki, Zakharia, Kais, Wang, Yu, Moser, Catherine D, Lim, John, O'Brien, Sean, Borad, Mitesh, Roberts, Lewis(2016). 11 The Casein Kinase II Inhibitor CX-4945 Has an Additive Effect With Gemcitabine and Cisplatin on Cholangiocarcinoma Xenografts. Gastroenterology. 150. (4). p. S4. WB Saunders

Devlin, Jennifer R, Hannan, Katherine M, Hein, Nadine, Cullinane, Carleen, Kusnadi, Eric, Ng, Pui Yee, George, Amee J, Shortt, Jake, Bywater, Megan J, Poortinga, Gretchen, et al.(2016). Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer discovery. 6. (1). p. 59--70. American Association for Cancer Research

Lee, Hans, Wang, Hua, Lin, Heather, Baladandayuthapani, Veera, He, Jin, Jones, Richard Julian, Kuiatse, Isere, Gu, Dongmin, Wang, Zhiqiang, O'Brien, Sean, et al.(2015). RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma. Blood. 126. (23). p. 3010. Content Repository Only!

Poortinga, Gretchen, Diesch, Jeannine, Sanij, Elaine, Hein, Nadine, Sornkum, Jirawas, Cameron, Donald, Bywater, Megan J, Johnstone, Ricky, Drygin, Denis, O'Brien, Sean, et al.(2015). Abstract A31: Elucidating mechanisms that cooperate with the therapeutic inhibition of RNA polymerase I to treat MYC-driven hematological malignancies. Molecular Cancer Therapeutics. 13. (10\_Supplement). p. A31--A31. The American Association for Cancer Research

Pearson, Richard B, Devlin, Jennifer R, Hannan, Katherine M, Hein, Nadine, Bywater, Megan J, Poortinga, Gretchen, Cameron, Donald, Drygin, Denis, O'Brien, Sean, Cullinane, Carleen, et al.(2014). Multi-point targeting of the synthetic lethal interactions between Myc, ribosome biogenesis and ribosome function cooperates to treat B-cell lymphoma. Cancer Research. 74. (19\_Supplement). p. 2735--2735. The American Association for Cancer Research

Hannan, R, Hein, Nadine, O’Brien, SE, Drygin, D, Cullinane, C, Matthews, G, Johnstone, RW, Pearson, RB, McArthur, G, Harrison, S, et al.(2014). Proffered Paper: Inhibition of RNA Polymerase I transcription by CX-5461 as a completely new approach to treat highly refractory haematological malignancies. Elsevier

Sheppard, Karen E, Brajanovski, Natalie, Hannan, Katherine M, Ahearn, Jessica, Ellul, Jason, Drygin, Denis, O'Brien, Sean, McArthur, Grant, Hannan, Ross D, Pearson, Richard B(2014). Targeting ribosome biogenesis with CX5461 as a potential treatment for melanoma and ovarian cancer. Cancer Research. 74. (19\_Supplement). p. 2718--2718. The American Association for Cancer Research

Drygin, Denis, O’Brien, Sean E, Hannan, Ross D, McArthur, Grant A, Von Hoff, Daniel D(2014). Targeting the nucleolus for cancer-specific activation of p53. Drug discovery today. 19. (3). p. 259--265. Elsevier Current Trends

Hein, Nadine, Drygin, Denis, O'Brien, Sean, Cullinane, Carleen, Matthews, Geoff, Chesi, Marta, Bergsagel, Leif, Zuber, Johannes, Lowe, Scott, Johnstone, Ricky, et al.(2013). Abstract B16: Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies. Cancer Research. 73. (19\_Supplement). p. B16--B16. The American Association for Cancer Research

Lee, Hans C, Wang, Hua, Li, Bing-Zong, Wang, Zhiqiang, Jones, Richard Julian, Gu, Dongmin, O'Brien, Sean, Davis, Richard E, Orlowski, Robert Z(2013). CX-5461, a novel RNA polymerase I inhibitor, is active against wild-type and mutant p53 myeloma models. Blood. 122. (21). p. 4438. Content Repository Only!

Hannan, Ross, Devlin, Jennifer, Hannan, Katherine, Hein, Nadine, Bywater, Megan, Poortinga, Gretchen, Cameron, Don, Drygin, Denis, Cullinane, Carleen, O'Brien, Sean, et al.(2013). Abstract PR16: Combined inhibition of ribosome function and ribosomal RNA gene transcription cooperate to delay relapse and extend survival in MYC-driven tumors. Cancer Research. 73. (19\_Supplement). p. PR16--PR16. The American Association for Cancer Research

Hein, Nadine, O'Brien, Sean, Drygin, Denis, Harrison, Simon J, Khot, Amit, Cullinane, Carleen, Geoff, Matthews, Chesi, Marta, Bergsagel, Peter Leif, Zuber, Johannes, et al.(2013). Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies. Blood. 122. (21). p. 3941. Content Repository Only!

Siddiqui-Jain, Adam, Bliesath, Joshua, Macalino, Diwata, Omori, Mayuko, Huser, Nanni, Streiner, Nicole, Ho, Caroline B, Anderes, Kenna, Proffitt, Chris, O'Brien, Sean E, et al.(2012). CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Molecular cancer therapeutics. 11. (4). p. 994--1005. American Association for Cancer Research

Bliesath, Joshua, Huser, Nanni, Omori, Mayuko, Bunag, Daniel, Proffitt, Chris, Streiner, Nicole, Ho, Caroline, Siddiqui-Jain, Adam, O’Brien, Sean E, Lim, John KC, et al.(2012). Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer letters. 322. (1). p. 113--118. Elsevier

Haddach, Mustapha, Michaux, Jerome, Schwaebe, Michael K, Pierre, Fabrice, O’Brien, Sean E, Borsan, Cosmin, Tran, Joe, Raffaele, Nicholas, Ravula, Suchitra, Drygin, Denis, et al.(2012). Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor. ACS medicinal chemistry letters. 3. (2). p. 135--139. American Chemical Society

Zanin, Sofia, Borgo, Christian, Girardi, Cristina, O'Brien, Sean E, Miyata, Yoshihiko, Pinna, Lorenzo A, Donella-Deana, Arianna, Ruzzene, Maria(2012). Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells. PLoS One. 7. (11). p. e49193. Public Library of Science

Haddach, Mustapha, Pierre, Fabrice, Regan, Collin F, Borsan, Cosmin, Michaux, Jerome, Stefan, Eric, Kerdoncuff, Pauline, Schwaebe, Michael K, Chua, Peter C, Siddiqui-Jain, Adam, et al.(2012). Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs. Bioorganic & medicinal chemistry letters. 22. (1). p. 45--48. Pergamon

Haddach, Mustapha, Schwaebe, Michael K, Michaux, Jerome, Nagasawa, Johnny, O'Brien, Sean E, Whitten, Jeffrey P, Pierre, Fabrice, Kerdoncuff, Pauline, Darjania, Levan, Stansfield, Ryan, et al.(2012). Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS medicinal chemistry letters. 3. (7). p. 602--606. American Chemical Society

Pierre, Fabrice, Regan, Collin F, Chevrel, Marie-Claire, Siddiqui-Jain, Adam, Macalino, Diwata, Streiner, Nicole, Drygin, Denis, Haddach, Mustapha, O’Brien, Sean E, Rice, William G, et al.(2012). Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorganic & medicinal chemistry letters. 22. (9). p. 3327--3331. Pergamon

Drygin, Denis, Bliesath, Joshua, Huser, Nanni, Proffitt, Chris, Siddiqui-Jain, Adam, Omori, Mayuko, Stansfield, Ryan, Macalino, Diwata, O'Brien, Sean E, Lim, John KC, et al.(2012). Discovery and biological characterization of CX-8184, a potent inhibitor of protein kinase CK2. Cancer Research. 72. (8\_Supplement). p. 3765--3765. American Association for Cancer Research

Pierre, Fabrice, Stefan, Eric, Nédellec, Anne-Sophie, Chevrel, Marie-Claire, Regan, Collin F, Siddiqui-Jain, Adam, Macalino, Diwata, Streiner, Nicole, Drygin, Denis, Haddach, Mustapha, et al.(2011). 7-(4H-1, 2, 4-Triazol-3-yl) benzo [c][2, 6] naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorganic & medicinal chemistry letters. 21. (22). p. 6687--6692. Pergamon

Drygin, Denis, Ho, Caroline, Bliesath, Josh, Proffitt, Chris, Bywater, Megan, Hannan, Ross, McArthur, Grant, O'Brien, Sean, Rice, William G, Anderes, Kenna(2011). CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers. Cancer Research. 71. (8\_Supplement). p. 4511--4511. American Association for Cancer Research

Siddiqui-Jain, Adam, Streiner, Nicole, Bliesath, Josh, Macalino, Diwata, Omori, Mayuko, Huser, Nanni, Ho, Caroline, O’Brien, Sean, Drygin, Denis, Anderes, Kenna(2011). CX-4945, an Inhibitor of Protein Kinase CK2, Potentiates the Antitumor activity of Platinum Chemotherapy in Models of Ovarian Cancer by Preventing Phosphorylation of XRCC1 and MDC1 and Disrupting DNA Damage Repair.

Marschke, RF, Borad, MJ, McFarland, RW, Alvarez, RH, Lim, JK, Padgett, CS, Von Hoff, DD, O'Brien, SE, Northfelt, DW(2011). Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. Journal of Clinical Oncology. 29. (15\_suppl). p. 3087--3087. American Society of Clinical Oncology

Pierre, Fabrice, O’Brien, Sean E, Haddach, Mustapha, Bourbon, Pauline, Schwaebe, Michael K, Stefan, Eric, Darjania, Levan, Stansfield, Ryan, Ho, Caroline, Siddiqui-Jain, Adam, et al.(2011). Novel potent pyrimido [4, 5-c] quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties. Bioorganic & medicinal chemistry letters. 21. (6). p. 1687--1691. Pergamon

Pierre, Fabrice, Chua, Peter C, O’Brien, Sean E, Siddiqui-Jain, Adam, Bourbon, Pauline, Haddach, Mustapha, Michaux, Jerome, Nagasawa, Johnny, Schwaebe, Michael K, Stefan, Eric, et al.(2011). Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Molecular and cellular biochemistry. 356. (1). p. 37--43. Springer US Boston

Drygin, Denis, Ho, Caroline B, Omori, Mayuko, Bliesath, Joshua, Proffitt, Chris, Rice, Rachel, Siddiqui-Jain, Adam, O’Brien, Sean, Padgett, Claire, Lim, John KC, et al.(2011). Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and biophysical research communications. 415. (1). p. 163--167. Academic Press

Drygin, Denis, Lin, Amy, Bliesath, Josh, Ho, Caroline B, O'Brien, Sean E, Proffitt, Chris, Omori, Mayuko, Haddach, Mustapha, Schwaebe, Michael K, Siddiqui-Jain, Adam, et al.(2011). Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer research. 71. (4). p. 1418--1430. American Association for Cancer Research

Battistutta, Roberto, Cozza, Giorgio, Pierre, Fabrice, Papinutto, Elena, Lolli, Graziano, Sarno, Stefania, O’Brien, Sean E, Siddiqui-Jain, Adam, Haddach, Mustapha, Anderes, Kenna, et al.(2011). Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 50. (39). p. 8478--8488. American Chemical Society

Pierre, Fabrice, Chua, Peter C, O’Brien, Sean E, Siddiqui-Jain, Adam, Bourbon, Pauline, Haddach, Mustapha, Michaux, Jerome, Nagasawa, Johnny, Schwaebe, Michael K, Stefan, Eric, et al.(2011). Discovery and SAR of 5-(3-chlorophenylamino) benzo [c][2, 6] naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. Journal of medicinal chemistry. 54. (2). p. 635--654. American Chemical Society

Anderes, K, Bliesath, J, Ho, C, Omori, M, Huser, N, Siddiqui-Jain, A, Streiner, N, Proffitt, C, O'Brien, S, Drygin, D(2010). 518 CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer. European Journal of Cancer Supplements. 8. (7). p. 165--166. Elsevier

Drygin, D, Bliesath, J, Siddiqui-Jain, A, Huser, N, Omori, M, Streiner, N, Proffitt, C, Ho, C, O'Brien, S, Anderes, K(2010). 99 Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models. European Journal of Cancer Supplements. 8. (7). p. 39. Elsevier

Lim, John KC, Padgett, Claire S, Marschke, Robert F, Northfelt, Donald W, Andreopoulou, Eleni, Von Hoff, Daniel D, Anderes, Kenna, Chen, Ta Kung, O'Brien, Sean E(2010). Utility of clinical biomarkers for detecting protein kinase CK2 inhibition: A report from the phase I trial of CX-4945. Cancer Research. 70. (8\_Supplement). p. 2763--2763. American Association for Cancer Research

Padgett, CS, Lim, JKC, Marschke, RF, Northfelt, DW, Andreopoulou, E, Von Hoff, DD, Anderes, K, Ryckman, DM, Chen, TK, O'Brien, SE(2010). 414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial. European Journal of Cancer Supplements. 8. (7). p. 131--132. Elsevier BV

Siddiqui-Jain, Adam, Drygin, Denis, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, O'Brien, Sean E, Bliesath, Josh, Omori, Mayuko, Huser, Nanni, Ho, Caroline, et al.(2010). CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer research. 70. (24). p. 10288--10298. American Association for Cancer Research

Ho, Caroline, Rice, Rachel, Drygin, Denis, Bliesath, Josh, Streiner, Nicole, Siddiqui-Jain, Adam, Proffitt, Chris, O'Brien, Sean, Anderes, Kenna(2010). CX-4945, a selective and orally bioavailable inhibitor of protein kinase CK2 inhibits PI3K/Akt, JAK-STAT and NF-$κ$B signaling and induces apoptosis in multiple myeloma cells. Blood. 116. (21). p. 787. Content Repository Only!

Anderes, KL, Streiner, N, Omori, M, Huser, N, Ho, C, Siddiqui-Jain, A, Bliesath, J, O'Brien, S, Drygin, D, Rice, WG(2010). Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer. Journal of Clinical Oncology. 28. (15\_suppl). p. e13522--e13522. American Society of Clinical Oncology

Bliesath, Josh, Drygin, Denis, Streiner, Nicole, Ho, Caroline, Siddiqui-Jain, Adam, Proffitt, Chris, Omori, May, Huser, Nanni, Bunag, Daniel, O’Brien, Sean, et al.(2010). The CK2 Inhibitor CX-4945 Enhances the Antitumor Activity of EGFR-targeted Agents by Attenuating Signaling in the PI3K-Akt-mTOR Pathway.

O'Brien, Sean, Haddach, Mustapha, Borsan, Cosmin, Michaux, Jerome, Kerdoncuff, Pauline, Schwaebe, Michael, Pierre, Fabrice, Stefan, Eric, Nedellec, Anne-Sophie, Siddiqui-Jain, Adam, et al.(2009). Abstract A246: Discovery of selective small molecule Pan-Pim kinase inhibitors with potent oral efficacy in murine xenograft models. Molecular Cancer Therapeutics. 8. (12\_Supplement). p. A246--A246. American Association for Cancer Research

Drygin, Denis, Bliesath, Josh, Ho, Caroline, Siddiqui-Jain, Adam, O'Brien, Sean, Omori, Mayuko, Huser, Nanni, Proffitt, Chris, Streiner, Nicole, Rice, William G, et al.(2009). Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells. Molecular Cancer Therapeutics. 8. (12\_Supplement). p. C198--C198. American Association for Cancer Research

Drygin, Denis, Bliesath, Josh, Ho, Caroline, Siddiqui-Jain, Adam, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, Omori, Mayuko, O'Brien, Sean, Rice, William, et al.(2009). Abstract# 145: CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated Hif-1$\backslash$# 945; transcription. Cancer Research. 69. (9\_Supplement). p. 145--145. American Association for Cancer Research

Anderes, Kenna, Siddiqui-Jain, Adam, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, Omori, May, Darjarnia, Levan, Stansfield, Ryan, Phung, Jennifer, Bliesath, Josh, et al.(2009). Abstract# 4660: Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated. Cancer Research. 69. (9\_Supplement). p. 4660--4660. American Association for Cancer Research

Drygin, Denis, Siddiqui-Jain, Adam, O'Brien, Sean, Schwaebe, Michael, Lin, Amy, Bliesath, Josh, Ho, Caroline B, Proffitt, Chris, Trent, Katy, Whitten, Jeffrey P, et al.(2009). Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer research. 69. (19). p. 7653--7661. American Association for Cancer Research

Anderes, KL, Siddiqui-Jain, Adam, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, Omori, May, Darjarnia, Levan, Stansfield, Ryan, Phung, Jennifer, Bliesath, Josh, et al.(2009). Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated. Breast. 1. (44). p. 28.

O'Brien, Sean, Haddach, Mustapha, Borsan, Cosmin, Michaux, Jerome, Kerdoncuff, Pauline, Schwaebe, Mike, Pierre, Fabrice, Stefan, Eric, Nedellec, Anne Sophie, Siddiqui-Jain, Adam, et al.(2009). Discovery of Selective Small Molecule Pan-Pim Kinase Inhibitors with Potent Oral Efficacy in Murine Xenograft Models. Blood. 114. (22). p. 1726. Content Repository Only!

Whitten, Jeffery, Drygin, Denis, Haddach, Mustapha, Ho, Caroline, Lin, Amy, Nagasawa, Johnny, O'Brien, Sean, Pierre, Fabrice, Trent, Katy, Rice, William(2008). CX-5461 selectively inhibits the SL1 Component of RNA Polymerase I in the ribosome biogenesis pathway and gives potent antitumor activity in models of cancer. Cancer Research. 68. (9\_Supplement). p. 3297--3297. American Association for Cancer Research

Drygin, Denis, Whitten, Jeffrey, Rice, William, O'Brien, Sean, Schwaebe, Michael, Lin, Amy, Ho, Caroline, Trent, Katy(2008). Quarfloxin (CX-3543) disrupts the Nucleolin/rDNA quadruplex complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor activity in models of cancer. Cancer Research. 68. (9\_Supplement). p. 3301--3301. American Association for Cancer Research

Siddiqui-Jain, Adam, Chua, Peter, Darjania, Levan, Lim, John, O'Brien, Sean, Pierre, Fabrice, Streiner, Nicole, Trent, Katy, Whitten, Jeffrey, Rice, William(2008). The discovery and characterization of CX-5011, a highly selective, potent inhibitor of Protein Kinase CK2. Cancer Research. 68. (9\_Supplement). p. 4875--4875. American Association for Cancer Research

O'Brien, Sean, Drygin, Denis, Ho, Caroline, Lim, John, Lin, Amy, Proffitt, Chris, Schwaebe, Michael, Siddiqui-Jain, Adam, Streiner, Nicole, Trent, Katy, et al.(2008). Ribosomal RNA biogenesis as a target for anti-cancer drug design. Cancer Research. 68. (9\_Supplement). p. 2356--2356. American Association for Cancer Research

O'Brien, Sean E, de Groot, Marcel J(2005). Greater than the sum of its parts: combining models for useful ADMET prediction. Journal of medicinal chemistry. 48. (4). p. 1287--1291. ACS Publications

O’Brien, Sean E, Brown, David G, Mills, James E, Phillips, Chris, Morris, Gregg(2005). Computational tools for the analysis and visualization of multiple protein--ligand complexes. Journal of Molecular Graphics and Modelling. 24. (3). p. 186--194. Elsevier

O'Brien, Sean E, Browne, Helen L, Bradshaw, Tracey D, Westwell, Andrew D, Stevens, Malcolm FG, Laughton, Charles A(2003). Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl) benzothiazoles to reactive intermediates by cytochrome P4501A1. Organic & biomolecular chemistry. 1. (3). p. 493--497. Royal Society of Chemistry

O'Brien, Sean E, Popelier, Paul LA(2002). Quantum topological molecular similarity. Part 4. A QSAR study of cell growth inhibitory properties of substituted (E)-1-phenylbut-1-en-3-ones. Journal of the Chemical Society, Perkin Transactions 2. (3). p. 478--483. Royal Society of Chemistry

O'Brie, SE, Popelier, Paul LA(2001). Quantum molecular similarity. 3. QTMS descriptors. Journal of Chemical Information and Computer Sciences. 41. (3). p. 764--775. American Chemical Society

O’Brien, Sean E, Popelier, Paul LA(2000). Quantum Molecular Similarity: Use of Atoms in Molecules derived quantities as QSAR variables. ECCOMAS Proceedings, Barcelona, Spain.

O'Brien, Sean E, Popelier, Paul LA(1999). Quantum molecular similarity. Part 2: The relation between properties in BCP space and bond length. Canadian journal of chemistry. 77. (1). p. 28--36. NRC Research Press Ottawa, Canada

Drygin, Denis, Bliesath, Josh, Ho, Caroline, Siddiqui-Jain, Adam, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, Omori, Mayuko, O'Brien, Sean, Schwaebe, Michael, et al.CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated Hif-1$α$ transcription. Migration. 110. p. 4945.

Siddiqui-Jain, Adam, Drygin, Denis, Streiner, Nicole, Chua, Peter, Pierre, Fabrice, O’Brien, Sean E, Bliesath, Josh, Omori, Mayuko, Huser, Nanni, Ho, Caroline, et al.treat NSCLC Menu.

CONFERENCE PAPER

Poortinga, Gretchen, Diesch, Jeannine, Sanij, Elaine, Hein, Nadine, Sornkum, Jirawas, Cameron, Donald, Bywater, Megan J, Johnstone, Ricky, Drygin, Denis, O'Brien, Sean, et al.(2015). Elucidating mechanisms that cooperate with the therapeutic inhibition of RNA polymerase I to treat MYC-driven hematological malignancies. MOLECULAR CANCER RESEARCH. 13.

Zakharia, Kais, Miyabe, Katsuyuki, Moser, Catherine D, O'Brien, Sean, Borad, Mitesh J, Roberts, Lewis R(2015). The Casein kinase II (CK2) inhibitor CX-4945 has an additive effect with gemcitabine and cisplatin on cholangiocarcinoma (CCA) cell lines mediated in part through PI3K/Akt inhibition. HEPATOLOGY. 62. p. 410A--410A.

Hannan, Ross, Devlin, Jennifer, Hannan, Katherine, Hein, Nadine, Bywater, Megan, Poortinga, Gretchen, Cameron, Don, Drygin, Denis, Cullinane, Carleen, O'Brien, Sean, et al.(2013). Combined inhibition of ribosome function and ribosomal RNA gene transcription cooperate to delay relapse and extend survival in MYC-driven tumors. CANCER RESEARCH. 73.

O'Brien, SE, de Groot, MJ(2004). Recursive partitioning, models and statistics: What can we extract from categorical data?. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 227. p. U692--U692.

Alvarado, Y, Brown, R, DiPersio, J, Verstovsek, S, Cortes, J, O'Brien, S, Sznol, M, Kantarjian, H, Fracasso, P, Giles, F(2002). Phase I study of Triapine (R), a novel ribonucleotide reductase inhibitor (RRI), in patients with refractory hematologic malignancies. BLOOD. 100. (11). p. 767A--767A.

Bradshaw, TD, Browne, HL, Hutchinson, I, Laughton, CA, Leong, CO, O'Brien, S, Stevens, MFG, Trapani, V, Westwell, AD(2001). Mechanistic studies and evaluation of clinical markers for Phortress, a new agent for clinical trials. British Journal of Cancer. 85. p. 103--103.

OTHER

Harrison, Simon J, Khot, Amit, Brajanovski, Natalie, Cameron, Don, Hein, Nadine, McArthur, Grant A, Lim, John KC, O'Brien, Sean, Ryckman, David M, Yu, Grace I, et al.(2015). A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM). American Society of Clinical Oncology

Drygin, Denis, O'brien, Sean E, Anderes, Kenna L, Von Hoff, Daniel, John, KC, Padgett, Claire S, Bliesath, Joshua R, Ho, Caroline B, Rice, William G, others(2011). Biomarkers for predicting the sensitivity and response of protein kinase CK2-mediated diseases to CK2 Inhibitors.

Haddach, Mustapha, O'brien, Sean, Anderes, Kenna(2010). Methods of treating disorders associated with protein kinase ck2 activity.

Drygin, Denis, Anderes, Kenna, Ho, Caroline B, Bliesath, Joshua R, Proffitt, Christopher B, O'brien, Sean, Rice, William G(2010). Treatment of neoplastic disorders using combination therapies.

O'brien, Sean, Siddiqui-Jain, Adam(2009). Methods for targeting quadruplex sequences.

Ryckman, David M, Drygin, Denis, Whitten, Jeffrey P, Anderes, Kenna, Trent, Katy, Darjania, Levan, Haddach, Mustapha, O'brien, Sean, Rice, William G(2008). Methods for treating aberrant cell proliferation disorders.

Whitten, Jeffrey P, O'brien, Sean(2008). Methods for treating ophthalmic disorders.

Darjania, Levan, O'brien, Sean(2008). Rapid analysis of oral bioavailability.

Drygin, Denis, Michelotti, Emil, O'brien, Sean, Rice, William, Siddiqui-Jain, Adam, Whitten, Jeffrey(2007). Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof.

Popelier, PLA, Aicken, FM, O’Brien, SE(2000). Chemical modelling: applications and theory. Royal Society of Chemistry Specialist Periodical Report. 1. p. 143--198.

DISSERTATION THESIS

O'Brien, Sean E(2000). Quantum Molecular Similarity: An Atoms in Molecules Approach.